12:00 AM
Feb 16, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

FV-100: Phase I data

Pooled data from 64 healthy volunteers in 2 double-blind, placebo-controlled Phase I trials showed that FV-100 was well tolerated with no adverse events. Pharmacokinetic data showed that all doses maintained mean drug plasma levels of the active form of FV-100 that exceeded EC50 for 24...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >